title: Evaluation of overnight hold of whole blood at room temperature before component processing: effect of red blood cell (RBC) additive solutions on in vitro RBC measures.
abstract: BACKGROUND
  Whole blood (WB) can be held at room temperature (18-25°C) up to 8 hours after collection; thereafter the unit must be refrigerated, rendering it unsuitable for platelet (PLT) production. Overnight hold at room temperature before processing has logistic advantages, and we evaluated this process in an international multicenter study for both buffy coat (BC)- and PLT-rich plasma (PRP)-based blood components and compared three red blood cell (RBC) additive solutions (ASs) for their ability to offset effects of overnight hold.
  
  
  METHODS
  Nine centers participated; seven used the BC method, and two used the PRP method. Four WB units were pooled and split; 1 unit was processed less than 8 hours from collection (Group A), and the other three (Groups B, C, and D) were held at room temperature and processed after 24 to 26 hours. RBCs in Groups A and B were resuspended in saline-adenine-glucose-mannitol, Group C in phosphate-adenine-guanosine-glucose-saline-mannitol, and Group D in ErythroSol-4 RBCs were stored at 2 to 6°C for 49 days.
  
  
  RESULTS
  RBCs from overnight-held WB had lower 2,3-diphosphoglycerate (2,3-DPG) and higher adenosine triphosphate (ATP). At the end of storage there were no differences between groups, apart from a slightly higher hemolysis in Group B. ErythroSol-4 showed a slightly higher initial ATP and 2,3-DPG content, but at the end of storage no differences were found.
  
  
  CONCLUSIONS
  Overnight hold of WB before processing has no lasting deleterious effects on in vitro quality of subsequently prepared components. The use of different RBC ASs did not appear to offer significant advantages in terms of RBC quality at the end, regardless of the processing method.
authors.affiliation: Department of Product and Process Development, Sanquin Blood Bank North West Region, Amsterdam, the Netherlands. p.vandermeer@sanquin.nl
authors.forename: Pieter F
authors.initials: PF
authors.lastname: van der Meer
authors.forename: Jose A
authors.initials: JA
authors.lastname: Cancelas
authors.forename: Rebecca
authors.initials: R
authors.lastname: Cardigan
authors.forename: Dana V
authors.initials: DV
authors.lastname: Devine
authors.forename: Hans
authors.initials: H
authors.lastname: Gulliksson
authors.forename: Rosemary L
authors.initials: RL
authors.lastname: Sparrow
authors.forename: Ralph R
authors.initials: RR
authors.lastname: Vassallo
authors.forename: Janny
authors.initials: J
authors.lastname: de Wildt-Eggen
authors.forename: Bärbel
authors.initials: B
authors.lastname: Baumann-Baretti
authors.forename: John R
authors.initials: JR
authors.lastname: Hess
mesh_terms: D000225:Adenine / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000097:blood; D001781:Blood Component Removal / Q000379:methods*; D001793:Blood Preservation / Q000379:methods*; D004912:Erythrocytes / Q000737:chemistry / Q000187:drug effects*; D005947:Glucose / Q000494:pharmacology*; D006019:Glycolysis / Q000187:drug effects; D006151:Guanosine / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D066298:In Vitro Techniques; D007552:Isotonic Solutions / Q000494:pharmacology*; D008353:Mannitol / Q000494:pharmacology*; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D012965:Sodium Chloride / Q000494:pharmacology*; D013696:Temperature; D013997:Time Factors
chemical_list: C037839:ADSOL; D007552:Isotonic Solutions; D019188:Organ Preservation Solutions; C430585:PAGGS-M solution; C098027:erythrosol; D006151:Guanosine; D008353:Mannitol; D012965:Sodium Chloride; D000255:Adenosine Triphosphate; D005947:Glucose; D000225:Adenine